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ABSTRACT
Background: Bone marrow aspiration and/or biopsy (BMAB) is a procedure used to diagnose 
and follow up various haematological diseases. It is usually performed at either the sternum or 
the iliac crest. Th e procedure oft en causes pain despite local infi ltration anaesthesia. 
Th e objective of this study was to evaluate diff erent means of pain relief during BMAB in 
adult patients. Special attention was paid to pre-procedural anxiety and its eff ect on pain. Th e 
commonly used local anaesthetic lidocaine was compared with articaine, an anaesthetic known 
for its ability to penetrate bone tissue. Th e eff ect of warming and buff ering the lidocaine solution, 
measures expected to improve the anaesthetic action, was examined. Also investigated were 
sublingual fentanyl and inhaled 50% nitrous oxide (N2O) in oxygen (O2) as means of analgesia 
and sedation during BMAB. 
Patients: Th e patient population comprised 646 adult outpatients from the Department of 
Haematology, Helsinki University Central Hospital, Finland. Patients were randomized to 
treatment groups in trials comparing one intervention with another or with placebo. Th e studies 
were all patient-blinded. One study was observational and investigated the association between 
pain and pre-procedural anxiety. Patient recruitment was performed between 2007 and 2014. 
Main results: Pre-procedural anxiety intensifi ed pain during BMAB in all trials. Median NRS 
(Numeral Rating Scale, 0 = no pain, 10 = worst pain imaginable) during infi ltration was 3.0 
(range 0 – 10, interquartile range (IQR) 3.0), puncture 2.0 (range 0 – 10, IQR 3.0), aspiration 
4.0 (range 0 – 10, IQR 4.0), biopsy 4.0 (range 0 – 10, IQR 4.0) and immediately aft er BMAB 0 
(range 0 – 9.0, IQR 1.0). Scores of 8 – 10 comprised 8.1%, 4.7%, 13.9%, and 12.4% of the scores 
for infi ltration, puncture, aspiration and biopsy, respectively. Possible supplemental analgesia or 
sedation given on patient request in addition to local anaesthesia and study intervention did not 
lower pain scores during BMAB. Articaine was not found to be superior to lidocaine as a local 
anaesthetic.  Warming and buff ering the lidocaine solution diminished pain during infi ltration, 
but did not lower the pain scores during other phases of BMAB. 
Sublingual fentanyl (200 μg or 100 μg) did not provide signifi cant pain relief relative to placebo 
when administered 6 – 64 minutes before BMAB. Dizziness was a frequent side-eff ect. Inhalation 
of 50% N2O in O2 was no more eff ective than inhalation of 50% O2. No signifi cant diff erences 
in adverse eff ects emerged between patients receiving N2O/O2 and those receiving 50% O2. 
Interestingly, 86% of N2O patients and 83% of placebo patients would choose the same analgesia 
method during their next BMAB. 
Conclusions: Many patients undergoing BMAB suff er intense pain during the procedure. Pre-
procedural anxiety was strongly associated with pain during the various phases of BMAB. Th e 
pain from local anaesthetic infi ltration with articaine and lidocaine was similar. Buff ering and 
warming the local anaesthetic solution clearly reduced the infi ltration pain. However, neither 
these measures nor the use of sublingual fentanyl or inhalation of N2O had an impact on the pain 
caused by aspiration and biopsy.
TIIVISTELMÄ
Tausta: Luuydinnäytteenotto (aspiraatio ja/tai biopsia) on toimenpide, jota tarvitaan erilaisten 
hematologisten sairauksien diagnostiikassa ja seurannassa. Näyte otetaan yleensä rintalastasta tai 
lonkkaluun harjanteesta. Toimenpide on usein kivulias paikallispuudutuksesta huolimatta.
Tutkimuksen tarkoituksena oli arvioida erilaisia kivunlievitysmenetelmiä aikuispotilailla, joilta 
otetaan luuydinnäyte. Erityistä huomiota kiinnitettiin toimenpidettä edeltävään ahdistuneisuuteen 
ja sen vaikutukseen toimenpidekipuun. Yleisesti käytettyä lidokaiinia verrattiin toiseen 
paikallispuudutteeseen artikaiiniin, jonka tiedetään läpäisevän hyvin luukudosta. Lidokaiiniliuoksen 
lämmittämisen ja puskuroinnin arvellaan parantavan puudutteen vaikutusta, joten tätä tutkittiin 
myös. Lisäksi tutkimuksessa arvioitiin kielen alle annostellun fentanyylitabletin sekä hengitettävän 
50% typpioksiduulin (N2O) ja hapen (O2) seoksen kipua lievittävää ja rauhoittavaa vaikutusta 
luuydinnäytteenoton aikana. 
Potilaat: Aineisto koostui 646 Helsingin yliopistollisen keskussairaalan hematologian osaston 
aikuisista avohoidossa olevista potilaista. Potilaat satunnaistettiin ryhmiin niissä tutkimuksissa, joissa 
yhtä interventiota verrattiin toiseen tai lumeeseen. Näissä tutkimuksissa potilaat sokkoutettiin. Lisäksi 
yhdessä havainnoivassa tutkimuksessa tutkittiin kivun ja toimenpidettä edeltävän ahdistuneisuuden 
yhteyttä. Potilasaineisto kerättiin vuosien 2007 – 2014 aikana. 
Tulokset: Toimenpidettä edeltävä ahdistuneisuus pahensi kipua luuydinnäytteenoton aikana 
kaikissa tutkimuksissa. NRS-mediaani (Numeral Rating Scale, 0 = ei kipua, 10 = pahin mahdollinen 
kuviteltavissa oleva kipu) puudutuksessa oli 3,0 (vaihteluväli 0 – 10, interkvartiilin vaihtelu (IQR) 3,0), 
pistossa 2,0 (vaihteluväli 0 – 10, IQR 3,0), aspiraatiossa 4,0 (vaihteluväli 0 – 10, IQR 4,0), biopsiassa 
4,0 (vaihteluväli 0 – 10, IQR 4,0) ja heti toimenpiteen jälkeen 0 (vaihteluväli 0 – 9,0, IQR 1,0). 
Korkeimpia pisteitä 8 – 10 antoivat 8,1% potilaista puuduttamisen, 4,7% piston, 13,9% aspiraation 
ja 12,4% biopsian aikana. Potilaan mahdollinen muu kipu- tai rauhoittava lääkitys puudutuksen ja 
tutkimuslääkeintervention lisäksi ei vähentänyt kipua luuydinnäytteenoton aikana. Artikaiini ei ollut 
lidokaiinia parempi paikallispuudutteena. Lidokaiiniliuoksen lämmittäminen ja puskurointi vähensi 
puudutuksen aiheuttamaa kipua, mutta ei vaikuttanut toimenpiteen muihin kivuliaisiin vaiheisiin.
Kielen alle annosteltu fentanyyli (200 μg tai 100 μg) ei merkittävästi vähentänyt toimenpidekipua 
lumeeseen verrattuna, kun se annosteltiin 6 – 64 minuuttia ennen toimenpidettä. Huimaus oli yleinen 
fentanyylin haittavaikutus. Hengitettävä 50% typpioksiduulin ja hapen seos ei ollut tehokkaampi 
kivunlievityksessä kuin lumekaasuna käytetty 50% happi. Typpioksiduulin ja hapen seosta saaneille 
potilaille ei kuitenkaan aiheutunut tilastollisesti merkitsevästi enempää haittavaikutuksia kuin 
lumekaasua saaneille. Peräti 86% typpioksiduulia ja 83% lumetta saaneista olisivat halunneet saman 
kaasun seuraavaan näytteenottoon. 
Johtopäätökset: Monelle potilaalle luuydinnäytteenotto aiheuttaa kovaa kipua. Toimenpidettä edeltävä 
ahdistuneisuus lisäsi selvästi kipua luuydinnäytteenoton eri vaiheissa. Happaman paikallispuudutteen 
infi ltraation aiheuttama kipu oli samanlainen artikaiinilla ja lidokaiinilla. Liuoksen puskurointi ja 
lämmitys selvästi vähensivät tätä infi ltraatiokipua. Artikaiinilla, puskuroinnilla ja lämmityksellä, 
kielen alle annostellulla fentanyylillä tai hengitetyllä typpioksiduulilla ei kuitenkaan ollut vaikutusta 
aspiraatio- tai biopsiakipuun. 
 
11  INTRODUCTION
Many diagnostic and therapeutic medical interventions cause pain that cannot be fully avoided. 
When a person encounters painful medical procedures repeatedly, the devastating eff ects of 
pain on mood and overall wellbeing are pronounced. Cancer suff erers and other chronically 
ill patients undergo several painful procedures – including bone marrow samplings – during 
the course of their illness. Performing the procedures may become more diffi  cult when patients 
suff er from pronounced anxiety, fear and nervousness. Is it acceptable that patients with a 
severe illness suff er signifi cant pain during diagnostic procedures? Obviously, the answer is no, 
as adequate pain relief has offi  cially been declared to be a human right (Brennan et al., 2007; 
Cousins and Lynch, 2011). 
Bone marrow aspiration and/or biopsy (BMAB) is performed frequently on the same 
patients since it is used in the diagnostics and follow-up of various haematological diseases. It 
involves puncturing the periosteum and the layer of compact bone with a puncture needle and 
aspiration of the bone marrow liquid with a syringe. Oft en a biopsy is needed as well. (Riley et 
al., 2004). Patients receive local anaesthetic infi ltration before the puncture, which in adults may 
be the sole mode of analgesia. Despite local infi ltration anaesthesia, puncture, aspiration and 
biopsy oft en cause signifi cant pain (Vanhelleputte et al., 2003; Lidén et al., 2009). Furthermore, 
the infi ltration of the acidic local anaesthetic solution (pH 3 – 4) may cause pain and discomfort. 
In some studies, premedication with oral opioids (Vanhelleputte et al., 2003) or benzodiazepines 
(Park et al., 2008) has proven useful. Despite these measures, control of pain originating from the 
bone and bone marrow during BMAB remains a major problem, at least in adults (Hjortholm et 
al., 2013). Children receive deep monitored sedation or general anaesthesia to control BMAB-
related pain.   
Anxiety is known to worsen pain during various medical procedures (Perrot et al., 2011; 
Weisensee et al., 2012) and aft er major surgery (Ozalp et al., 2003). It has been shown to also 
intensify pain during BMAB (Lidén et al., 2009). Th us, specifi cally targeting anxiety may be 
benefi cial in the control of pain during BMAB. 
Lidocaine is probably the most oft en used local anaesthetic during BMAB. Th e adrenaline-
containing solution is very acidic; its pH can be as low as 3 (Tetzlaff , 2000). Th is oft en causes 
tissue irritation and pain during infi ltration. Buff ering the local anaesthetic solution with sodium 
bicarbonate has been noted to decrease pain during infi ltration (Xia et al., 2002; Ruegg et al., 
2009).Th e rise in pH reduces the dissociation of the lidocaine molecule, which enhances its 
capability to enter nerve cells and act rapidly on sodium channels (Coventry and Todd, 1989; 
Quinlan et al., 1992). Th is may lead to better anaesthesia of the infi ltrated tissue area compared 
with acidic solutions. In addition to buff ering, warming the local anaesthetic solution has been 
shown to reduce pain during infi ltration (Hogan et al., 2011).
Th e eff ect of local anaesthetics is limited, however. Th e distribution of the solution in the 
tissue may sometimes be inadequate and the solution does not always reach the deeper layers 
of bone tissue. Articaine, an amide-linked local anaesthetic popular in dentistry (Evans et al., 
2008), is known to diff use in bone tissue more eff ectively than lidocaine (Vree and Gielen, 2005). 
It may be useful in BMABs as well, as the procedure primarily involves the bone tissue of the 
sternum or iliac crest. 
 To manage pain originating from puncture, aspiration and biopsy in adults, supplemental 
analgesia is oft en needed. Th e medication administered should be quickly eff ective but short-
acting, as BMABs are predominantly performed in outpatient clinics that do not have the 
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2resources of long-term monitoring of patients. Furthermore, many patients return to work 
or other duties soon aft er the procedure, and thus, the side-eff ects of the analgesics should be 
tolerable and temporary.
Fentanyl is a potent opioid that has long been used for rapid pain relief. Due to its considerable 
fi rst-pass metabolism in the liver, the drug has been administered primarily parenterally in 
order to achieve suitable bioavailability. It has been administered via transmucosal (oral, nasal), 
transdermal and intravenous routes (Grape et al., 2010). Recently, a new sublingual formulation 
of the drug was developed. Sublingual fentanyl is primarily aimed at relieving breakthrough pain 
in cancer patients. Due to its high degree of liposolubility, fentanyl traverses the oral mucosa 
rapidly and thus acts fast (Fine and Streisand, 1998). However, the number of studies examining 
sublingual fentanyl in acute pain settings other than cancer is limited. Sublingual fentanyl 
might be an eff ective analgesic given before BMAB, and the pharmacokinetic profi le of the drug 
formulation warrants further investigations. 
Nitrous oxide (N2O) has been used in clinical practice for over 150 years. It is widely used 
as a safe analgesic during labour pain (Rosen, 2002), and is frequently used during general 
anaesthesia as a hypnotic and analgesia adjuvant. Due to its low solubility in blood, a steady state 
between inhaled and alveolar N2O partial pressures is reached quickly, and its actions are evident 
within a couple of minutes (Becker and Rosenberg, 2008). Once the patient ceases to inhale, the 
gas is rapidly eliminated and the possible mild side-eff ects (dizziness, headache) resolve quickly. 
Th us, in theory and based on a few small-scale studies (Steedman et al., 2006; Gudgin et al., 
2008; Johnson et al., 2008), it might be a suitable analgesic during BMAB. 
In these trials, the aim was to control procedural pain during outpatient BMAB with diff erent 
pharmacological means without having to utilise the intravenous route. Special attention was 
paid to anxiety prior to the procedure and its infl uence on pain during BMAB. Th e occurrence of 
adverse eff ects of the methods used was investigated as a secondary outcome. 
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2.1  Bone marrow aspiraƟ on and biopsy
2.1.1  Structure and histology of bone and bone marrow
Th e periosteum is the outermost layer of bone tissue. It is relatively thin and composed of fi brous 
connective tissue. It also comprises a network of sensory nerve fi bres (Mach et al., 2002). A layer 
of compact mineralized bone is located beneath it. Compact bone surrounds the marrow cavity, 
which contains sponge-like bone tissue. Bone marrow is located within the spaces of this spongy 
bone tissue. Bone marrow comprises haematopoietic cells, fat cells, protein, water and blood 
vessels. (Ross et al., 2003) Bone marrow is richly innervated by sensory and autonomic nerves. 
Th e number of sensory fi bres is larger in bone marrow than in the other bone compartments 
(Mach et al., 2002). 
Th e sensory nerve fi bres responsible for pain perception in the periosteum, mineralized 
bone and bone marrow are primarily of a specifi c peptide-poor subset of nociceptive C-fi bres, 
which form mesh-like networks within bone tissue together with a subset of myelinated A-fi bres 
(Freeman et al., 2008; Jimenez-Andrade et al., 2010). Th e distribution of these subsets of nerve 
fi bres is diff erent from that of skin tissue, and they ascend to a diff erent region in the spinal cord 
than nerve fi bres from skin (Jimenez-Andrade et al., 2010), at least in a rat model. However, 
the bone marrow also receives autonomic innervation, and especially the adrenergic subtype of 
autonomic nerve fi bres participates in the regulation of haematopoietic function (Lucas et al., 
2013).  
Th e marrow of most bones in an adult comprises primarily fat cells. However, some bones, 
such as the sternum, vertebrae, iliac crest, ribs and proximal ends of the femur and humerus, 
retain their marrow’s haematopoietic stem cell activity also during adulthood (Ross et al., 2003; 
Wang and Berliner, 2007). Th e marrow of these bones produces the red blood cells, many 
subtypes of the white blood cells, and platelets that enter the circulation aft er maturation. 
However, during some haematological disorders the normal function of the bone marrow is 
distorted and abnormal cells may emerge. Some bone regions containing haematopoietically 
active marrow are suitable for bone marrow aspirations and biopsies for examination in these 
situations, providing the anatomy is suitable for the sampling procedure. 
2.1.2  History of bone marrow aspiraƟ on and biopsy
Bone marrow sampling for diagnostic purposes has been used for the last 100 years. During 
this period several kinds of needles and instruments have been introduced into clinical practice 
(Parapia, 2007). Th e basic structure and function of the puncture needles for both bone marrow 
aspirations and biopsies today resemble markedly those in the 1950s. Th e newest innovation 
is a powered needle drill (Voigt and Mosier, 2013). Th e powered technique seems, however, to 
have gained more attention for use in emergency intraosseal cannulations than for diagnostic 
punctures. Th e bone marrow examination is a central and usually indispensable tool in both 
haematological diagnostics and follow-up, and the benefi ts of the examination include nowadays 
also the possibility to use modern applications of molecular biology and immunology. 
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42.1.3 Indica? ons for bone marrow aspira? on and biopsy
Many haematological disorders cannot be specifi cally diagnosed or excluded in samples of 
peripheral blood, and thus, examination of bone marrow is needed (Islam, 1997). BMAB is needed 
in diagnostics of malignant diseases, such as acute or chronic leukaemias, multiple myeloma, 
lymphomas or metastatic tumors of non-haematological origin (e.g. carcinomas). Other diseases 
diagnosed or specifi ed with BMAB are myelodysplastic syndromes, myeloproliferative states, 
some anaemias, cytopenias and amyloidosis. Bone marrow examination may be needed for 
the diagnosis of some infectious diseases, e.g. tuberculosis. In addition, BMAB is frequently 
needed during follow-up of these diseases aft er established diagnosis and treatment such as 
chemotherapy, modern targeted therapy or stem cell transplantation. (Riley et al., 2004) Th e 
procedure is performed on healthy bone marrow donors as well.
2.1.4  Performing bone marrow aspira? on and biopsy
Before performing BMAB, the patient should receive information on the indications and 
technical aspects of the procedure and also on possible adverse eff ects. Th e laboratory values, 
especially haemoglobin value and thrombocyte count, should be checked and attention paid to 
coagulation parameters, at least in patients on warfarin medication. 
Th e puncture area is inspected and carefully palpated to check the anatomy and possible 
deviations from the normal in the region and to choose the optimal site. Aft er disinfection of 
the skin, a local anaesthetic is infi ltrated into the skin, subcutaneous tissue and to the proximity 
of periosteum. Aspiration is performed with single-use, disposable or reusable 16 – 14G needles 
from either the sternum or the posterior iliac crest. Th e needle is inserted through the skin, 
subcutis and periosteum with slow rotating movements through the cortical dense bone. When 
the resistance gets lighter, the needle tip has reached the marrow cavity. A sample of the liquid 
bone marrow is then aspirated into a syringe. If a biopsy is needed, it is obtained from the iliac 
crest. Th e bone marrow biopsy is performed with a thicker needle, and pressure and rotatory 
movement are required to get the sample from the marrow (Riley et al., 2004). Once the samples 
have been taken, a bandage is applied on the puncture wound. Th e needles used to obtain the 
samples are presented in Figure 1. Figures 2 and 3 present the aspiration and biopsy, respectively. 
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Figure 1. Aspiration and biopsy needles.
5 Figure 2. Bone marrow aspiration.  Figure 3. Bone marrow biopsy.
2.1.5  Complica? ons
BMABs are relatively safe procedures with the risk for complications varying between 0.07% 
and 0.12%. Haemorrhage is the most common complication. (Bain, 2004; 2006; Kuivalainen et 
al., 2013) Th e haemorrhage is usually minor (Valebjørg et al., 2014) and may cause small bruises 
or haematomas. However, there are reports of major haemorrhages to the retroperitoneal space 
aft er puncture of the iliac crest (Eikelboom, 2005; Tsai et al., 2008), and haemorrhage-associated 
nerve damage (Roth and Newman, 2002). Infections of the puncture site may also occur. Th e 
sternal puncture may, especially if also the posterior cortex is penetrated, be complicated 
by cardiac tamponade (Bhootra, 2004) or pneumothorax (Bain, 2003). In addition to acute, 
procedural pain, BMAB has been reported to cause long-term pain (Bain, 2004). If sedation is 
used, it seems that it is relatively safe in a selected patient population (Burkle et al., 2004).
Complications can be avoided to a large extent with careful planning of the procedure and 
cautious palpation and disinfection of the puncture area. However, complications cannot be 
totally avoided, and thus, patients should be carefully monitored aft er BMAB, e.g. with questions 
regarding their condition, possible pain, dizziness or other symptoms. If the patient feels unwell, 
closer monitoring, such as blood pressure and peripheral oxygen saturation measurements, may 
be indicated. 
2.2  Acute pain
Th e International Association for the Study of Pain has defi ned pain as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage or described in terms 
of such damage” (Anon, 1979). It can be regarded as a useful signal of tissue damage and harm, 
thus encouraging the avoidance of noxious factors. However, pain causes suff ering as well, and 
when it cannot be avoided, the emotional stress may be devastating. 
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62.2.1  Pathophysiology of acute pain
Trauma, surgery or other medical procedures as well as numerous diseases cause tissue injury 
with various mechanical, chemical or thermal stimuli. Direct tissue trauma leads to activation of 
nociceptive nerve fi bres, but it also leads to the release of chemical transmitters, such as cytokines 
and other infl ammatory mediators, neurotransmitters and growth factors, which further activate 
nociceptive nerves (Carr and Goudas, 1999). Th ese infl ammatory mediators are known to 
increase the fi ring frequency of the nociceptors, which leads to intensifi ed pain sensation (Momin 
and McNaughton, 2009). Th e nociceptive stimuli are transferred in aff erent nerve fi bres (C and 
A fi bres) to the brain via the spinal cord (Carr and Goudas, 1999). Various factors may aff ect the 
transmission; anti- and pronociceptive factors, for instance, may manipulate the stimuli in the 
spinal cord via the descending pathways (Apkarian et al., 2005). Many psychological factors, such 
as anxiety, fear, attention and expectations, belong to factors modifying pain sensation (Rainville, 
2002). Th ese descending pathways originate from various cortical areas and descend through 
several routes via, for example the amygdala and hypothalamus to the dorsal horn of spinal 
cord, where they interact with the nociceptive stimuli originating from the tissue (Apkarian et 
al., 2005). When the modifi ed impulses fi nally reach the brain, the stimuli distribute to several 
sensory cortical areas; the sensation of pain has been generated.  Acute pain does not usually last 
long relative to chronic pain, although the division of the two is not always straightforward; they 
can be regarded as a continuum rather than two separate states (Carr and Goudas, 1999; Cousins 
et al., 2000). 
2.2.2  RaƟ ng scales for assessment of acute pain
Objective tools for assessing pain are non-existent as the sensation of pain is personal, subjective 
and multidimensional. However, in pain research and various clinical settings, the intensity 
and sometimes the quality of pain need to be somehow assessed. Various tools are available 
to measure acute pain intensity and its quality (Table 1). Th e most commonly used tools for 
measuring intensity are the Numeral Rating Scale (NRS), the Visual Analogue Scale (VAS) and 
the Verbal Rating Scale (VRS). Th ese have been proven to be valid and reliable (Williamson 
and Hoggart, 2005). Th e Red Wedge Scale (RWS), developed from the VAS, may also be used 
especially aft er major surgery (Tigerstedt and Tammisto, 1988; Pesonen et al., 2008; 2009). Th e 
NRS and VAS scores can be further quantifi ed as mild, moderate and severe pain; the cut-off  
points for these have varied in diff erent studies. A reduction of 30% – 50% in pain scores has 
implied a clinically signifi cant change in diff erent studies (Williamson and Hoggart, 2005). 
Th ese scales have been shown to be somewhat more sensitive than VRS (Breivik et al., 2000). 
Th e intensity of pain in children can be measured with the Faces Pain Scale – Revised (Hicks et 
al., 2001) or the Maunuksela scale (Maunuksela et al., 1987), as the NRS, VAS and VRS may be 
diffi  cult to use in younger children due to the tests’ demands on cognitive capacity. However, in 
the demented elderly, VRS seems to be the most suitable pain rating scale (Pesonen et al., 2009).
A valuable tool to assess the quality of pain is the McGill Pain Questionnaire (MPQ) 
(Melzack, 1975; Campbell and Vowles, 2008) and it’s short form (SF-MPQ). It is predominantly 
used with chronic pain suff erers, but is also useful in assessing the quality of acute pain. Th e 
questionnaire has been shown to be valid and it is widely used. It has been translated and 
validated into several languages, including Finnish (Ketovuori and Pöntinen, 1981). 
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Table 1. Tools to assess pain intensity and its quality.
Scale Scoring Use in clinical practice Features
Numeral Rating 
Scale (NRS)
0 = no pain
10 = worst pain imaginable. 
Also 21- and 101-point 
scales have been used.
Patient indicates the 
number describing pain 
intensity.
Illustrates pain intensity. 
Can be used verbally or 
graphically.
Visual Analogue 
Scale (VAS)
100-mm line, where 0 
mm indicates no pain and 
100 mm the worst pain 
imaginable. 
Patient indicates the point 
of pain intensity on the 
line.
Illustrates pain intensity. 
Can be used horizontally 
or vertically. 
Red Wedge Scale 
(RWS)
50-cm wedge, where the 
left  edge indicates no pain 
and the right edge the 
worst pain imaginable.
Patient indicates the point 
of pain intensity with a 
moving vertical pointer on 
a red-coloured horizontal 
wedge. Th e score is the 
point on the VAS line on 
the reverse side of the line.
Illustrates pain intensity. 
Based on VAS. May be 
more illustrative or simpler 
to use aft er major surgery 
than the traditional VAS.
Verbal Rating 
Scale (VRS)
Adjectives, such as no pain, 
mild pain, moderate pain, 
severe pain. Th ese may be 
further assigned numbers.
Patient expresses the 
suitable adjective verbally 
or in writing.
Illustrates pain intensity. 
Ordinal variable in which 
the intervals are not linear.
Faces Pain Scale 
– Revised 
(FPS-R)
Comprises 6 images of 
faces expressing pain of 
worsening intensity. First 
face = no pain, last face = 
excruciating pain.
Th e child points to the face 
best representing the pain 
intensity. 
Illustrates pain intensity 
in children over 4 years. 
Intervals are close to linear. 
Can be scaled to numerals 
0 – 5 or 0 – 10. 
Maunuksela 
Pain Scale
0 = no pain, 9 = worst 
possible pain. A scale of 0 – 
10 has also been used.
An adult trained observer 
assesses the intensity of 
pain. Th e assessment is 
based on various fi ndings 
such as facial expressions 
and movement of limbs. 
Observer-based scale that 
illustrates pain intensity 
in children based on 
assessment of behavioural 
parameters. 
McGill Pain 
Questionnaire 
(MPQ)
Comprises 78 sensory, 
aff ective and evaluative 
words, categorized to 20 
groups. Words are further 
scored within groups to 
obtain the pain rating 
index (PRI). Includes VRS 
0 – 5 as well. 
Patient fi lls out the MPQ 
with a pen, although verbal 
administration is possible 
as well. 
Illustrates the sensory 
and aff ective quality of 
pain, and pain intensity is 
separately illustrated with a 
6-point VRS. 
2.2.3  Pain associated with medical procedures
Patients undergo various medical procedures, ranging from major surgery to minor outpatient 
interventions. In 2012, there were 645 038 treatments in Finnish hospitals that included a medical 
procedure in somatic specialist medical care. Of these treatments, 427 766 were surgical and 109 
962 were non-surgical and non-radiological (National Institute for Health and Welfare; http://
urn.fi /URN:NBN:fi -fe201312207698). In Finland, approximately 10 000 BMABs are performed 
annually (Kuivalainen et al., 2013). Many of these procedures are painful, requiring various 
8means of sedation, pain relief and anaesthesia. Th e impact of procedural pain on health care 
costs and well-being is signifi cant. 
Acute postoperaƟ ve pain
Despite the use of multimodal pain relief and various follow-up protocols conducted with acute 
pain service teams, moderate to severe acute pain aft er surgery is common. Th e prevalence of 
severe pain is estimated to be roughly 10% at rest, while moderate pain is slightly more common, 
ranging from 30% to 36% (Cousins et al., 2000; Dolin et al., 2002). Th ere is some variation in 
these proportions of pain intensity, depending on the type and location of the procedure. In 
another study (Sommer et al., 2008) investigating the prevalence of postoperative pain, 26% of 
patients reported moderate pain and 15% reported severe pain one hour aft er the operation at 
rest. In this study, higher pain ratings were associated with abdominal and spinal/back surgery 
or surgery of the upper/lower extremities. Furthermore, younger age, female gender, general 
anaesthesia and major surgery intensifi ed the pain. In a study performed on patients undergoing 
ambulatory surgery (Gramke et al., 2007), the proportion of patients reporting moderate to 
severe pain on the day of the operation was 26%, most pain being related to surgery involving 
the nose, pharynx, abdomen and breasts and to orthopedic operations. Th ese patients are usually 
discharged on the day of operation and their pain should be treatable at home.
Acute procedural pain
Pain during less invasive medical procedures is also common. During colonoscopy non-sedated 
patients reported severe pain in 20% and moderate pain in 34% of cases (Hoff man et al., 1998). 
However, in another study (Takahashi et al., 2005), also performed with non-sedated patients, 
most patients (71.2%) did not report pain at all during colonoscopy. Interestingly, in this study 
only 0.7% of participants were willing to undergo the next colonoscopy without sedation, 
indicating that the procedure causes considerable discomfort. Pain was related to young age, low 
BMI, fi rst-timers and previous hysterectomy, amongst others. 
In a study investigating the prevalence of pain related to liver biopsy, 60% of patients 
reported moderate or severe pain during the fi rst hour aft er the biopsy (Eisenberg et al., 2003). 
In a smaller pilot study (Castéra et al., 1999), 20% of participants reported a VAS score of over 40 
mm (on a scale from 0 to 100 mm) during the biopsy. 
Pain during dental care is also frequent. In a meta-analysis investigating pain before, 
during and aft er root canal treatment, pain prevalence during treatment was 11% – 100% (Pak 
and White, 2011). However, the proportion of patients suff ering severe pain during treatment 
was low. In another study, pain during root canal treatment was less intense than during other 
frequently performed dental procedures (Rousseau et al., 2002). In a questionnaire-based 
study, 42.5% of those having had dental treatment over a 5-year follow-up reported pain during 
treatment; 19.1% reported that pain was moderate or severe (Maggirias and Locker, 2002).  
In summary, many types of procedures and treatments cause pain of at least moderate 
intensity. While pain may not be fully eliminated, attention should be paid on the methods 
making the procedural pain tolerable. Furthermore, if the patients need to undergo several 
painful procedures due to e.g. cancer, the importance of adequate pain relief is highlighted. In 
cancer patients, pain originating from various procedures is a signifi cant factor in the overall 
burden of pain (Ripamonti et al., 2014), and thus, should be targeted adequately.
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2.3.1  Mechanisms of the eﬀ ect of anxiety on pain
Humans make observations during the course of their lives in various situations, encounters 
and mental states.  Th rough the eff ect of learning, these observations form memories and 
eventually aff ect the expectations that a person has of a specifi c situation. Over time, these 
previous experiences and expectations have an impact on the person’s pain behaviour (Loeser 
and Melzack, 1999). Th e specifi c mechanism for this has been shown in a study using fMRI 
imaging (Ploghaus et al., 2001); anxiety and negative expectation of pain modify activation in 
the hippocampus, specifi cally the entorhinal cortex. Th e hippocampal activity further aff ects 
the adjacent areas responsible for aff ective states and intensity coding. However, anxiety aff ects 
other brain areas in the descending pathways as well (Apkarian et al., 2005), eventually leading to 
intensifi ed pain perception. Since variation exists in people’s individual histories and expectations 
and their impact on neural circuitries, the eff ect of anxiety on pain is also individualistic: some 
patients may not be fearful at all, e.g. at a dental appointment, whereas others may be terrifi ed. 
2.3.2  Measuring acute anxiety
Th ere are numerous tests available that measure the intensity of anxiety in various clinical 
settings. Th ese are useful in clinical research as well. However, these tests vary with regard to the 
specifi c type of anxiety being evaluated. Some tests measure acute, state anxiety, whereas others 
are validated to measure more chronic anxiety, anxiety disorders or a trait of anxiety. When 
acute, procedure-related anxiety is evaluated, the tests used should be specifi cally validated to 
measure the desired variable. 
Th e intensity of acute, procedural anxiety may be evaluated with various verbal rating scales 
(e.g. none, mild, moderate, intense) or numeral rating scales (e.g. 0 – 10, where 0 = no anxiety, 
10 = worst anxiety imaginable). Th ese scales have been proven to be valid and suitable in busy 
clinical settings (Benotsch et al., 2000). Th ere are also tests validated to measure dental anxiety 
specifi cally (Aartman, 1998; Humphris et al., 2000). Th e fear of pain questionnaire has been 
developed to measure general fear related to pain (McNeil and Rainwater, 1998).
Th e Spielberger State-Trait Anxiety Inventory (STAI) (Spielberger and Vagg, 1984; 
Spielberger, 2010) is a widely used validated test that has two distinct parts. Th e state part 
(STAI-S) measures anxiety as a mental state, i.e. acute anxiety related to acute stressful events. 
It has been used in various clinical studies investigating the relationship between anxiety and 
acute pain. Th e trait part (STAI-T) measures more chronic anxiety, i.e. trait anxiety. Both parts 
consist of 20 items each. Th e items in STAI-S have four alternative answers (not at all, somewhat, 
moderately so, very much so), which are further scored with a scoring key. Th e range of scores is 
20 – 80 for STAI-S, with higher scores indicating a higher intensity of anxiety.  
2.3.3  Anxiety and pain during medical procedures
Th e patient’s specifi c clinical situation has an eff ect on anxiety: patients about to undergo major 
surgery are anxious about, for instance, the outcome, postoperative ability to function and how 
the family will cope, whereas patients having a minor medical intervention, such as a dental 
procedure, are mainly anxious about aspects of the procedure itself (Oosterink et al., 2008; 
Powell and Johnston, 2008). However, although the procedure may not be harmful or carry any 
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high risks of serious adverse eff ects (e.g. visit to the dentist), the pre-procedural anxiety may 
nevertheless vary due to diff erences in personality traits and exposure to conditioning stimuli. 
Anxiety remains one of the major factors predicting procedural pain. 
Anxiety and postoperaƟ ve pain
Preoperative anxiety has been proposed to have a complex association with postoperative 
pain through various pathways (Kain et al., 2000). Highly anxious patients suff er more intense 
postoperative pain and consume more analgesics during the postoperative phase (Ip et al., 2009) 
than less anxious patients. Th is has been noted also in the paediatric population (Kain et al., 
2006). Since inadequately treated pain during the postoperative period has many adverse eff ects 
(Joshi and Ogunnaike, 2005), it is important to treat also the risk factor for pain, pre-procedural 
anxiety. Risk factors for preoperative anxiety include history of malignancy and smoking, 
depression and other negative psychological traits, pain, female gender, higher level of education, 
medium-level surgery and poor physical health (Caumo et al., 2001). 
Anxiety and pain during diagnosƟ c procedures 
Anxiety is associated with pain during colonoscopy (Ylinen et al., 2009). Th e association between 
anxiety and pain could also be seen in a study investigating non-pharmacological anaesthesia 
adjuncts (Schupp et al., 2005) during radiological procedures. Interestingly, in this study, the 
state anxiety levels decreased during the procedures, indicating that procedure-related anxiety 
is at its highest level prior to and at the beginning of a painful procedure. Anxiety is also known 
to intensify pain during outpatient cystoscopy (Goldfi scher et al., 1997) and prostate biopsy 
(Tekdogan et al., 2008). 
Anxiety and dental procedural pain
Th e connection between anxiety and pain during dental procedures is well established 
(Maggirias and Locker, 2002; Klages et al., 2004; Weisensee et al., 2012).  In addition to anxiety, 
catastrophizing intensifi es dental procedural pain (Sullivan and Neish, 1998). Patient features 
associated with dental anxiety include depression, generalized anxiety and simple phobias, 
substance dependence, previous invasive dental treatment (Locker et al., 2001) and previous 
exposure to traumatic events (de Jongh et al., 2006). 
Anxiety and pain during dental procedures can be alleviated or eliminated with, for 
example, psychological methods (Skaret and Soevdsnes, 2005), oral premedication (Ehrich et al., 
1997), inhaled nitrous oxide (Hallonsten et al., 1983), intravenous sedation (Oei-Lim et al., 1998) 
or even general anaesthesia (Dougherty, 2009).  
Anxiety and pain during BMAB
Bone marrow aspirations and biopsies cause pain and anxiety.  During the observational phase of 
a study investigating patients undergoing BMAB, the proportion of patients suff ering moderate 
pain during aspiration was 19.7% and severe pain 15.9% (Vanhelleputte et al., 2003). In another 
study (Lidén et al., 2009), 56% of patients reported procedural pain of moderate intensity, 
32% pain of severe intensity and 3% the worst possible pain. In that study as well as in another 
observational study (Brunetti et al., 2011), anxiety was strongly associated with procedural 
pain. In a questionnaire-based study, pain was scored as “bearable” by 59.6% and “unbearable” 
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by 3.7% of patients (Degen et al., 2010). In that study, pain suff ered during previous BMABs 
predicted pain during subsequent BMABs, and inadequate information regarding BMAB was 
also seen as a factor intensifying pain. Th e study did not measure anxiety. Furthermore, many 
patients had received premedication, although the authors concluded that premedication did not 
aff ect pain scores. Other factors reported to be associated with pain during BMAB are female 
gender, age, pre-existing pain prior to BMAB, patient’s socio-economic status, experience of the 
performing haematologist and procedural factors (such as length of procedure) (Vanhelleputte 
et al., 2003; Lidén et al., 2009; Talamo et al., 2010). Generally speaking, patients consider pain 
caused by BMAB to be so intense that they oft en desire sedation and analgesia in addition to 
local anaesthetic infi ltration (Kuball et al., 2004; McGrath et al., 2013). Furthermore, medical 
professionals may overlook or underestimate pain and anxiety during BMAB (Kuball et al., 2004; 
Lidén et al., 2012). Th ere are also reports of inconsistent registration of the level of pain suff ered 
and considerable variation in premedication protocols (Sollazzo et al., 2014). 
2.4  TreaƟ ng pre-procedural anxiety and pain during bone marrow 
aspiraƟ on and biopsy
Studies of varying methodological quality have examined several means of pain relief during 
BMAB in adults. Trials that were randomized, controlled and investigated pharmacological 
methods are summarized in Table 2. Studies not controlled and/or randomized are reviewed or 
mentioned in the text only. 
2.4.1  Local anaestheƟ cs
Local anaesthetics are agents that cause numbness and analgesia through various mechanisms: 
aft er traversing the cell membrane and inhibiting the voltage-gated sodium channel, they 
antagonize the infl ux of sodium ions into nerve cells, inhibiting depolarization and propagation 
of the impulse to the central nervous system. Th is eff ect is intensifi ed with blockade of potassium 
and calcium channels and some G-protein receptors. (McLure and Rubin, 2005) However, 
many factors, such as pH and the neuronal sheath, infl uence the kinetics of molecules’ infl ux 
into nerve cells (Leeson and Strichartz, 2013). Local anaesthetics have several administration 
routes: infi ltration into the skin and subcutaneous tissue (local anaesthesia) or to the proximity 
of nerves (peripheral nerve blocks, plexus blocks), application to the surgical area, intrathecal or 
epidural space administration (neuraxial anaesthesia/analgesia) or intravenous administration 
to a limited region or as continuous systemic infusion. In conjunction with local anaesthesia, 
adrenaline may be added to the local anaesthetic solution as a vasoconstrictor, which prolongs 
the eff ect (Liu et al., 1995) and reduces haemorrhage in the procedure area (Wilmink et al., 
1998). Local anaesthetics can be divided into amides, esters, ketones or ethers according to their 
chemical structure, amides being the most popular in clinical anaesthesiology (McLure and 
Rubin, 2005). 
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Lidocaine
Lidocaine belongs to the amide group of local anaesthetics. It is widely used in local anaesthesia, 
and the majority of the published studies investigating pain and anxiety during BMAB in adults 
have used it as a local anaesthetic (Table 2).  It is fast-acting, and due to a moderate protein 
binding ability, it is also relatively short-acting (McLure and Rubin, 2005). At room temperature, 
its pKa is 7.7 – 7.9, which means that in acidic solution the molecule is predominantly in its 
ionized form. Th e pH of the commercial lidocaine solutions is usually 5.0 – 6.0, but if adrenaline 
is added, pH is lowered. Th e elimination half-life of lidocaine is 45 – 60 minutes. (Tetzlaff , 2000) 
Lidocaine is metabolized in the liver and further eliminated via the kidneys (McLure and Rubin, 
2005). Th e molecular structure of lidocaine is presented in Figure 4.
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Figure 4. Structural formulas of A. articaine and B. lidocaine.
ArƟ caine
Articaine belongs to the amide group as well, but in addition, the molecule contains an ester 
group (Figure 4). Its pKa is similar to that of lidocaine. Th e pH of the commercial solutions is 
around 5.0 (Steele et al., 2009). It has a tiophene ring, which increases the molecule’s liposolubility. 
Th us, articaine is known for its ability to penetrate bone tissue better than lidocaine (Vree and 
Gielen, 2005; Skjevik et al., 2011). It is fast-acting and quickly hydrolysed by esterases in tissues 
and plasma, which shortens the elimination time (Vree and Gielen, 2005). Due to its ability to 
infi ltrate bone tissue eff ectively, it has been widely used in dentistry, where its analgesic capacity 
has been noted to be at least equal to that of lidocaine (Vähätalo et al., 1993; Malamed et al., 
2000). However, in a recent meta-analysis summarizing the relevant studies comparing articaine 
and licocaine, the analgesic eff ect of articaine in dentistry was found to be superior to that of 
lidocaine (Katyal, 2010). 
In addition to local anaesthesia, articaine has been used with promising results in spinal 
anaesthesia (Bachmann et al., 2012), epidural anaesthesia (Noyan et al., 2000; Katircioglu et 
al., 2008), nerve blocks (Simon et al., 1999) and intravenous regional anaesthesia (Simon et al., 
1997). However, no previous studies have investigated its use during BMAB. 
Buﬀ ering and warming the local anaestheƟ c
Local anaesthetic solutions are usually acidic (pH 5 – 7), which ensures that the molecules are 
in their ionized, soluble form. Furthermore, addition of adrenaline to the solution requires even 
lower pH in order to preserve the drug in its active form. However, these acidic solutions cause 
pain during infi ltration due to tissue irritation. Raising the pH by adding sodium bicarbonate, 
i.e. buff ering, has been shown to cause less pain from skin infi ltration before various procedures, 
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including BMAB (Xia et al., 2002; Ruegg et al., 2009; Kashyap et al., 2011; Welch et al., 2012). 
Since pH has a major role in regulating the local anaesthetic molecule’s ability to traverse the 
nerve cell membrane (McLure and Rubin, 2005), it is logical that raising the pH of the local 
anaesthetic solution would have an eff ect on the analgesic capacity of the solution. In fact, the rise 
in pH has been shown to enhance the passage of the molecules to the nerve cells and facilitate the 
onset (Coventry and Todd, 1989; Quinlan et al., 1992; Kashyap et al., 2011) and intensity (Ruegg 
et al., 2009) of anaesthesia, although contradictory results also exist (Whitcomb et al., 2010). 
In a recent meta-analysis, warming the local anaesthetic solution was shown to alleviate pain 
during infi ltration to a clinically signifi cant extent, compared with room temperature solutions 
(Hogan et al., 2011). In fact, warming and buff ering have been demonstrated to have synergistic 
eff ects (Mader et al., 1994; Colaric et al., 1998). Th us, combining these two simple methods can 
lead to marked pain relief during local anaesthetic administration and possibly lead to a better 
analgesia as well. No earlier studies have evaluated the combined eff ect of warming and buff ering 
during BMAB.
2.4.2  Opioids
Overview of opioids
Opioids are chemical agents that bind to specifi c opioid receptors in the central and peripheral 
nervous system as well as in peripheral tissues (Trescot et al., 2008; Pasternak, 2014), which leads 
to eff ective pain relief. Endogenous opioids are responsible for pain relief in placebo analgesia 
(Riet et al., 1998; Zubieta et al., 2005), among other functions. Opioids can be classifi ed according 
to their chemical structure. Th ese drugs have distinctive and unique pharmacokinetic and 
-dynamic profi les (Trescot et al., 2008). Opioids may be administered in various ways: peroral, 
parenteral (intravenous, intramuscular, transmucosal, transdermal), spinal or epidural.  Th e 
release of the drug can be further modifi ed (rapid or controlled release), thus meeting the specifi c 
needs of the patient. Th e side-eff ects of opioids (e.g. dizziness, sedation, respiratory depression, 
constipation, pruritus, nausea, tolerance) are predominantly dose-dependent (Trescot et al., 
2008), although some adverse eff ects, such as constipation, may occur with smaller doses as 
well. Furthermore, chronic use of opioids frequently causes addiction, and thus, opioids may 
be abused (Compton and Volkow, 2006). Th e indications for use vary from minor conditions 
(e.g. headache, musculoskeletal pain) to cancer pain management and perioperative treatment of 
pain. When opioid medication is considered, the indication, the patient’s characteristics and the 
drug’s pharmacologic profi le determine which preparation is chosen.  
Sublingual fentanyl
Fentanyl is a strong opioid belonging to the phenylpiperidine class of opioids (Trescot et al., 2008). 
It has a relatively rapid onset of action. Due to moderate fi rst-pass metabolism in the liver aft er 
oral administration, it has been administered primarily via the parenteral route. Furthermore, 
it is a highly lipophilic molecule, which makes it ideal for transmucosal administration, i.e. 
through oral or intranasal mucosa. (Grape et al., 2010) A “lollipop” or lozenge formulation of 
fentanyl for transmucosal administration has been used for several years for acute breakthrough 
pain in cancer patients and also during some medical procedures (Fine and Streisand, 1998). A 
new sublingual formulation of the drug has been developed as well, with better bioavailability. 
When administered sublingually, the peak fentanyl concentration is reached in 40 – 55 minutes, 
the fi rst detectable concentrations occurring 8 – 10 minutes aft er administration. (Lennernäs et 
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al., 2005). Sublingual fentanyl has been shown to be eff ective in acute cancer breakthrough pain, 
the side-eff ects being similar to other opioids (Lennernäs et al., 2010).
In the paediatric population, oral transmucosal fentanyl in the lollipop formulation was 
found to be superior to placebo during BMABs or lumbar punctures (Schechter et al., 1995), 
but nausea and vomiting may restrict its use in this indication. Th ere are no prior studies 
investigating the usefulness of sublingual fentanyl in adult patients undergoing BMAB.
Other opioids during BMAB
A few studies have investigated the analgesic capacity of the following opioids in adults undergoing 
BMAB: tramadol (Vanhelleputte et al., 2003), hydromorphone combined with lorazepam 
(Dunlop et al., 1999; Wolanskyj et al., 2000) and oxycodone combined with paracetamol and 
lorazepam (Talamo et al., 2010). However, some of these studies are not randomized or even 
placebo-controlled, which limits their clinical relevance. In conclusion, evidence of eff ective 
and feasible opioid premedication in adults prior to BMAB is insuffi  cient and further studies 
regarding this issue are needed. 
2.4.3  Benzodiazepines 
Benzodiazepines relieve anxiety and induce sedation. Th ey are GABAA receptor agonists. 
Increased GABAA receptor activity results in an increase in inhibitory activity in the brain, which 
leads to sedation, anxiolysis and anticonvulsive eff ects (Lader, 1987). Benzodiazepines also 
have an impact on the brain’s memory function, which leads to anterograde amnesia, at least 
with midazolam (Bulach et al., 2005). Benzodiazepines can be divided into short-acting (e.g. 
triazolam) and long-acting (e.g. diazepam), depending on the specifi c pharmacological profi le 
(Lader, 1987). Benzodiazepines have been extensively used during various medical procedures as 
sedatives, as anticonvulsants and as anxiolytics in psychiatry. Side-eff ects, such as tiredness and 
respiratory depression, may occur with larger doses. With long-term use, tolerance and adverse 
eff ects on cognitive function are also frequent (Stewart, 2005). Furthermore, benzodiazepines 
may be abused (O’Brien, 2005).  
Several studies have examined the use of benzodiazepines during BMAB in adults (Milligan 
et al., 1987; Dunlop et al., 1999; Wolanskyj et al., 2000; Giannoutsos et al., 2004; Chakupurakal 
et al., 2008; Park et al., 2008); some of these studies have investigated the combined eff ect of an 
opioid and benzodiazepine. In summary, most of the studies did not show any benzodiazepine-
related reduction in pain scores. Th ese drugs appear to be eff ective in causing amnesia, and they 
might increase patients’ co-operation. Th e use of benzodiazepines might be justifi ed, especially 
in anxious patients, but their long-lasting sedative eff ect restricts their use in outpatient clinics. 
2.4.4  Nitrous oxide
Th e mixture of nitrous oxide (N2O) and oxygen (O2) has been used for over 150 years as a 
hypnotic and an analgesic during various medical procedures (Masood et al., 2002; Aboumarzouk 
et al., 2011) and during labour (Rosen, 2002) and as an adjuvant in general anaesthesia. N2O is a 
gas at room temperature and normal atmospheric pressure, and it liquefi es at -89.5 °C (Trogler, 
1999). It has no unpleasant smell or fl avour. N2O has low solubility in blood and adipose tissue, 
which leads to a short onset of action (within a couple of minutes) aft er the start of inhalation 
(Becker and Rosenberg, 2008). Once it reaches the brain, it seems to have many modes of 
action: activation of antinociceptive descending pathways through endogenous opioid release, 
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NMDA receptor antagonism, GABAA agonist release as well as an eff ect on dopamine and α2 
adrenoceptors (Maze and Fujinaga, 2001; Emmanouil and Quock, 2007). Once inhalation of 
N2O ceases, the gas redistributes rapidly from the blood to the alveoli and is further exhaled. 
Such side-eff ects as headache and dizziness are mild and temporary. Over time or with frequent 
use, nitrous oxide is known to disturb vitamin B12 metabolism, but this is not the case during 
short medical procedures (Weimann, 2003). Although administration of N2O is relatively easy, 
the adverse eff ects on health care personnel during extensive exposure to N2O (Sanders et al., 
2008) should be kept in mind and gas scavenging systems should always be used. According 
to Finnish regulations (Finnish Institute of Occupational Health), the 8-hour time-weighted 
average N2O concentration in room air should not exceed 100 ppm. 
Inhaled N2O has been useful in procedural sedation and analgesia in children (Reinoso-
Barbero et al., 2011) and during venous cannulations in both children (Hee et al., 2003) and 
adults (Gerhardt et al., 2001). It has also proven useful during minor procedures in adults 
(Meskine et al., 2011; Hierons et al., 2012). Furthermore, intraoperative use of N2O has been 
shown to reduce the risk for chronic postoperative pain (Chan et al., 2011). Use of N2O might 
be benefi cial in such minor procedures as BMAB, as reports have been made of prolonged pain 
aft er BMAB (Bain, 2004). 
Some studies have examined the usefulness of N2O/O2 during BMAB (Steedman et al., 
2006; Gudgin et al., 2008; Johnson et al., 2008) in the adult population. Only one of these studies 
was randomized and blinded (Johnson et al., 2008), and the patient populations (48 participants) 
was relatively small. In that study, N2O/O2 was eff ective in males but not in females. Some studies 
have been conducted with paediatric population, with varying results (Annequin et al., 2000; 
Iannalfi  et al., 2005). However, in those studies additional medications, such as benzodiazepines, 
were oft en used. Additional randomized and placebo-controlled studies are needed before N2O/
O2 can be regarded as an eff ective pain-relieving method during BMAB in adult patients. 
2.4.5  Other analgesics and sedaƟ ves
One study investigated the eff ects of conscious sedation performed with inhaled methoxyfl urane 
during BMAB (Spruyt et al., 2013), with promising results. Aft er all, methoxyfl urane has been 
shown to increase pain threshold already at subanaesthetic concentrations (Tomi et al., 1993). 
Deeper sedation with other anaesthetic agents is less oft en used in adult outpatients undergoing 
BMAB. However, children usually undergo the BMAB in deep sedation or general anaesthesia 
(Krauss and Green, 2006). Th us, most studies examining deep sedation during BMAB are 
conducted with paediatric patient populations. Th ese studies vary with regard to the medication 
used. Th ere are reports of combinations of opioids and propofol (Holdsworth et al., 2003; 
Anghelescu et al., 2013), combinations of propofol, midazolam and ketamine (Po et al., 2012) 
and ketamine alone (Evans et al., 2008). In general, deep sedation or general anaesthesia was 
found to be eff ective in reducing procedural pain in children. 
Non-pharmacological methods
Pain during BMAB can be alleviated, at least to some extent, by paying attention to the mechanical 
performance of the procedure. Although traditional needles applied manually are still common, 
new powered devices for obtaining biopsy samples from the iliac crest have been developed. 
Th ese devices seem to cause less pain during bone marrow biopsy, and they help to obtain longer 
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biopsy samples, with no signifi cant rise in complication rates. (Voigt and Mosier, 2013) During 
aspiration a slow aspiration technique causes less pain than a rapid technique, although rapid 
aspiration leads to better sample quality (Hasselgren et al., 2014).
Some studies have investigated the effi  cacy of psychological means of pain relief during 
BMAB, such as hypnosis (Snow et al., 2012), music therapy (Danhauer et al., 2010; Shabanloei et 
al., 2010) and art therapy (Favara-Scacco et al., 2001), as well as combined use of psychological 
methods and pharmacological pain relief and sedation (Lord and Bhuller, 2012). A study 
comparing magnetic acupressure with sham acupressure (pressure applied to sham acupuncture 
points) showed no statistically signifi cant diff erence in median pain scores between the treatment 
arms (Bao et al., 2011). Th e authors suggested that the proportion of patients suff ering intense 
pain was higher in the sham group, but due to the small sample size, this eff ect is probably not 
clinically signifi cant.  
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3  AIMS OF THE STUDY
Th e objective of this study was to assess the effi  cacy of various analgesic methods on the intensity 
of pain suff ered by adult patients during bone marrow aspiration and/or biopsy and to examine 
the role of anxiety and other factors in the pain experience. Specifi c aims were as follows: 
1.  To measure pain intensity and quality and to assess prevalence and intensity of pre-
procedural anxiety and its eff ect on pain ratings during BMAB. Specifi c interest was paid 
to possible diff erences between the experience of pain during BMAB in fi rst-timers as 
compared with those having undergone BMAB before (Studies I, II, III, IV, V).
2.  To compare analgesic effi  cacy of articaine and lidocaine infi ltration of the tissue layers 
between the skin and bone during the various phases of BMAB (Study II).
3.  To assess the analgesic effi  cacy of warming and buff ering the infi ltrated lidocaine solution 
on pain during BMAB (Study III).
4.  To evaluate the analgesic effi  cacy and side-eff ects of sublingual fentanyl relative to placebo 
during BMAB (Study IV).
5.  To assess the analgesic effi  cacy and safety of inhalation of 50% nitrous oxide in oxygen 
compared with 50% oxygen during BMAB (Study V). 
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4 PATIENTS AND METHODS
4.1  PaƟ ents
Th is study comprised 646 patients. Th e participants were outpatients at the Department of 
Haematology, Helsinki University Central Hospital, undergoing bone marrow aspiration and/or 
biopsy. Common exclusion criteria in Studies I – V were unstable coronary artery disease, allergy 
to lidocaine or articaine, BMI over 32 kg/m2 and inability to communicate in Finnish or Swedish. 
Inability to give informed consent due to, for example, dementia, other cognitive impairment or 
poor condition led to exclusion as well. Patients scheduled for BMAB were telephoned before 
the procedure day and notifi ed of the study protocol (Studies IV – V). Written information was 
provided on the procedure day. All consecutive patients scheduled to have BMAB on days when 
the research team was present were considered for inclusion, providing that they did not fulfi l 
the exclusion criteria. Th e fi nal decision on enrolment was made by the research assistant on 
these predefi ned criteria or by one of the researchers. All patients enrolled in the studies gave 
written informed consent. Th e patient enrolment took place between 2007 and 2014.  
Study I
Th e study comprised 166 patients; 48 were fi rst-timers for BMAB. All patients were enrolled only 
once. 
Study II
Th e study comprised 150 patients, of whom 50 received articaine 20 mg/ml, 49 received articaine 
40 mg/ml, and 51 patients received lidocaine 20 mg/ml. All solutions contained adrenaline 5 μg/
ml. A couple of patients were enrolled two times due to the long study period, and on the second 
enrolment the patient was allocated to another study group.
Study III
Th e study comprised 100 patients, half of whom were randomized to receive warmed and 
buff ered lidocaine and the other half served as a control group, receiving room-temperature, 
unmodifi ed lidocaine. Th e solutions contained adrenaline 5 μg/ml. Th e warmed and buff ered 
solution was prepared a couple of minutes before infi ltration to ensure adequate preservation. 
All patients were enrolled only once. 
Study IV
Th e study comprised 160 patients, half of whom were randomized to receive sublingual fentanyl 
and the other half placebo. Th e study-specifi c exclusion criteria were drug abuse or ongoing 
opioid replacement therapy, predetermined analgesic premedication for the procedure, driving 
own car or lack of a competent escort. Th e patient could participate only once. 
Study V
In total, 70 patients were randomized to receive either inhaled 50% nitrous oxide in oxygen (35 
patients) or 50% oxygen (35 patients). Th e study-specifi c exclusion criteria were emphysema or 
chronic obstructive pulmonary disease (COPD), pneumothorax, Alzheimer’s disease or other 
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cognitive impairment, pregnancy and predetermined analgesic or anxiolytic premedication for 
the procedure. All patients were enrolled only once. 
4.2  Pre-procedural interviews
Aft er giving written informed consent, the participants were interviewed. Th e interview consisted 
of the following information:
1.  Demographic data, diagnosis or indication for BMAB.
2.  Current medications used for pain and anxiety (Studies I, III – V) and for arterial 
hypertension (Studies IV, V).
3.  Th e grade of pre-procedural anxiety, assessed with STAI-S (Study I), NRS 0 – 10 (Studies III 
– V), or on the scale 0 – 4, where 0 = no anxiety, 4 = very anxious (Study II).
4.  Pre-existing pain and its intensity on the NRS 0 – 10 (Studies I, III – V).
5.  Pain during previous BMABs and other minor medical procedures, graded as no pain – 
slightly painful – very painful (Studies I, III, V).
6.  Letter Digit Coding Test (Houx et al., 2002) to obtain the baseline score of the participant’s 
cognitive capacities (Study V). Th e Finnish version of the test is presented in the Appendix. 
Th e test consists of rows of letters, which need to be coupled with specifi c numbers given in 
a separate key. Th e score is the number of correctly combined letter-number pairs fi nished 
in a given time. 
4.3  Procedure
Some patients received analgesic premedication (intramuscular alfentanil 0.5 – 1 mg) (Studies I, 
III) or anxiolytic premedication (oral diazepam 5 – 10 mg) (Studies I – IV), given upon patient 
request 30 – 60 minutes before BMAB. Th ese drugs served also as rescue medication in case of 
extreme pain or anxiety during BMAB in addition to study drugs (Studies II – V). 
With the patient lying down, non-invasive blood pressure was measured (Studies IV, 
V). In Study IV, the stage of sedation was also evaluated at this point on the Ramsay Sedation 
Scale (RSS) (Ramsay et al., 1974). Th e patient then received local anaesthetic infi ltration to the 
procedure area in standardized volumes of 6 ml (sternal manubrium), 8 ml (sternal body) or 10 
ml (posterior iliac crest). Th e local anaesthetic used was lidocaine 20 mg/ml with adrenaline 5 
μg/ml (Studies I, IV, V), lidocaine 20 mg/ml or articaine 20 mg/ml or articaine 40 mg/ml, all with 
adrenaline 5 μg/ml (Study II), warmed lidocaine 20 mg/ml with adrenaline 5 μg/ml buff ered with 
sodium bicarbonate or room-temperature lidocaine 20 mg/ml with adrenaline 5 μg/ml added to 
0.9% NaCl (Study III). In all of the studies, one-third of the total volume was infi ltrated to the 
skin, one-third to the subcutaneous tissue and the remaining one-third in the close proximity of 
the periosteum. Aft er the infi ltration, the procedure area was disinfected and draped. Th e local 
anaesthetic was left  to take eff ect for at least two minutes before beginning the BMAB.   
Th e performing physician tested the adequacy of local anaesthesia with the puncture 
needle. If the local anaesthesia was insuffi  cient, another dose (half of the original volume) of the 
local anaesthetic was infi ltrated. Th e physician then performed the aspiration and, if needed, the 
biopsy as well. Th e biopsy was always taken from the posterior iliac crest. 
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Aft er completion of the BMAB, the puncture area was covered with a bandage and 
the patient received instructions on how to monitor the puncture site and how to treat post-
procedural pain. Th e patient was discharged aft er the study interviews if the patient felt well and 
no signs of bleeding or other complications were present. 
4.4  IntervenƟ ons
Study I
Th e study was observational, thus, the patients received no study-specifi c intervention other 
than the standardized local anaesthesia. All patients received lidocaine 20 mg/ml with adrenaline 
5 μg/ml (Lidocain c. Adrenalin, Orion Pharma, Espoo, Finland). 
Study II
Patients were randomized to receive either articaine 20 mg/ml, articaine 40 mg/ml (Ultracain, 
Sanofi -Aventis, France) or lidocaine 20 mg/ml (Lidocain, Orion Pharma, Espoo, Finland). 
Adrenaline (Adrenalin, Leiras Takeda Pharmaceuticals, Helsinki, Finland) was added to all of 
the solutions to yield a concentration of 5 μg/ml. 
Study III
Patients were randomized to receive either warmed and buff ered lidocaine or room-temperature, 
unmodifi ed lidocaine. Warmed and buff ered lidocaine solution was made from 8 ml of lidocaine 
20 mg/ml with adrenaline 5 μg/ml (Lidocain c. Adrenalin, Orion Pharma, Espoo, Finland) and 2 
ml of sodium bicarbonate 75 mg/ml (Natriumbicarbonate Braun 75 mg/ml, B. Braun, Melsungen, 
Germany). Before mixing these two solutions, they were warmed in separate syringes to 32˚C 
under a heating lamp. Aft er warming, these were mixed in one syringe. Th e solution for the 
control group was made from 8 ml of lidocaine 20 mg/ml with adrenaline 5 μg/ml (Lidocain c. 
Adrenalin, Orion Pharma, Espoo, Finland) added to 2 ml of NaCl 0.9% solution. Th is solution 
was kept at room temperature. In conclusion, in both groups the total volume of local anaesthetic 
solution was 10 ml with the same lidocaine concentration, but with diff erent temperature and 
pH (7.3 in the warmed and buff ered solution, 3.7 in the control solution). 
Study IV
All study participants received lidocaine 20 mg/ml with adrenaline 5 μg/ml (Lidocain c. 
Adrenalin, Orion Pharma, Espoo, Finland). Patients randomized to the fentanyl group (80 
participants) received sublingual fentanyl 200 μg (Abstral®, ProStrakan Ltd, Galashiels, Scotland, 
UK), but if the patient was in poor health, weighed less than 50 kg or was over 70 years old, the 
dose given was 100 μg. Patients randomized to the placebo group (80 participants) received a 
similar, rapidly dissolving tablet without any pharmacologically active ingredients. Th e patient 
received the tablet 10 – 30 min before the procedure was assumed to begin. 
Study V
Patients randomized to the N2O/O2 group (35 participants) were given a double mask (Medicvent 
AB, Umeå, Sweden), which was connected to a single-use fi lter and a valve that triggered gas 
fl ow only during suffi  ciently deep inhalation. When the patient breathed through the mask, 50% 
N2O/O2 (Livopan®, the Linde Group, Germany) was administered during inhalation. Th e exhaled 
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gas was led from the mask via plastic hoses to a device (Excidio®, the Linde Group, Germany) 
breaking N2O down to nitrogen and oxygen, thus reducing N2O pollution.
Patients randomized to placebo (35 patients) received 50% oxygen through a mask attached 
to a ventilation bag (Laerdal silicone resuscitator, Stavanger, Norway) further connected to a 
rotameter providing fresh gas fl ow of 10 l/min. 
Th e patients were advised to start inhalation 2 – 3 minutes before the beginning of local 
anaesthetic infi ltration. Th e local anaesthetic was lidocaine 20 mg/ml with adrenaline 5 μg/
ml (Lidocain c. Adrenalin, Orion Pharma, Espoo, Finland). Patients were advised to breathe 
continuously through the mask throughout the procedure to ensure adequate analgesia, but they 
were allowed to have pauses as well. In this case, the patient was advised to restart inhalation 2 
– 3 minutes before the next painful phase of BMAB. Aft er the BMAB was complete, the patient 
ceased the inhalation. 
4.5  Tests for pain and post-procedural interviews 
Th e research assistant interviewed the patient 30 – 60 minutes aft er the procedure. It was 
assumed that the peak eff ect of the study medication had worn off  (Studies IV-V) by this time. 
Th e participant answered questions regarding general condition, possible side-eff ects of the study 
drugs and pain felt aft er the BMAB. In Study IV, the patient’s peripheral oxygen saturation was 
monitored as well. Th e respiration rate was monitored in Studies IV and V. Th e Numeral Rating 
Scale (NRS, 0 – 10) was used in all studies to measure procedural pain intensity. In Studies II – IV, 
the patient scored the pain felt during the phases of the procedure (local anaesthetic infi ltration, 
puncture, aspiration, biopsy) when the BMAB was still ongoing. In Studies I and V, the pain 
scores were obtained aft er the procedure, during the post-procedural interview. In addition, 
in Study I, the patients were asked to describe the pain using the Finnish pain vocabulary 
(Ketovuori and Pöntinen, 1981).  
During the telephone interview on the following day the patients answered questions 
regarding their general condition, post-procedural pain and possible pain medication taken as 
well as possible complications aff ecting the puncture site. In Study II, the patient was telephoned 
also two weeks aft er the procedure and the same questions were repeated. Either the research 
assistant or another member of the research group performed these interviews. 
4.6  Blinding and randomizaƟ on
Study I was observational and did not include any randomization or blinding. In Studies II – 
V, randomization was performed with sealed envelopes. In Study II, one of the non-blinded 
researchers prepared the used local anaesthetic solutions in a room separate from the procedure 
room. Th is researcher did not participate in patient enrolment or interviews, and thus, the study 
was kept double-blind. Th e performing physician was kept blind as well. 
In Study III, the non-blinded research assistant prepared the local anaesthetic solution aft er 
the patient was enrolled and interviewed, that is, just before the beginning of the BMAB. Th is 
study was only patient-blinded. 
In Study IV, a nurse assisting the performing physician and not otherwise involved in the 
study opened the envelope and gave the sublingual tablet (fentanyl or placebo) to the participant 
according to the instructions on the envelope. Th us, Study IV was double-blinded, as the patient, 
the performing physician and the research assistant performing the interviews were kept blinded 
regarding the drug administered. 
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In Study V, a member of the research group opened the randomization envelope in the 
procedure room and made the preparations for the allocated gas, just before the patient entered 
the room. Th e patient and the research assistant performing the interviews were kept blinded 
to the gas used. Regardless of the study group, the non-blinded researcher gave the patients 
the same instructions on how to use the mask. Due to visible diff erences in gas administration 
equipment between the two study arms, it was not possible to keep the assisting personnel or the 
performing physician blinded. However, they handled the patient similarly regardless of the gas 
used.  
Aft er the BMAB, patients were not asked about which randomization group they thought 
they had been assigned. 
4.7  StaƟ sƟ cs
Th e sample size in every trial was based on a power calculation. Th e normality of the variables 
was assessed with the Shapiro-Wilk test. Th e NRS scores as well as variables measuring anxiety 
were not normally distributed. Th us, in all studies, the majority of the analyses were conducted 
with non-parametric tests. In Studies I and III – V, the diff erences in pain scores between study 
groups were analysed with ordinal regression analysis. Factors assumed to have a confounding 
eff ect (e.g. age, gender, pain or anxiolytic medication) were included in the analysis. In Study 
II, the pain and anxiety scores between the three groups were analysed with the Kruskal-Wallis 
test. ANOVA was used when appropriate. Th e Mann-Whitney U test was used in unadjusted 
comparisons (Studies I, II) and the Χ2 –test in comparison of proportions between groups (Study 
I).
Logistic regression analysis was used in Studies IV and V to assess the side-eff ects of the 
study drugs used. Th ese analyses were adjusted for factors assumed to have a confounding eff ect. 
In Study V, logistic regression analysis was used also to assess whether diff erences were present in 
cognition test results between the groups. SPSS versions 16.0, 17.0 and 22.0, and PASW version 
18.0 (IBM, New York, NY, USA) were used in the analyses. A P-value < 0.05 was considered to 
be statistically signifi cant. Th e results are presented as mean, median, standard deviation (SD), 
percentage, interquartile range (IQR), odds ratio (OR) and its confi dence intervals (CI). 
4.8  Ethics
In every trial, participants gave written informed consent before randomization. Patients unable 
to speak and understand Finnish or Swedish were excluded, as were patients diagnosed with 
dementia or another cognitive impairment (e.g. mental disability) preventing full understanding 
of the trial. Th e hospital ethics committee of the Helsinki and Uusimaa Hospital District 
approved all trials. In addition, the former Finnish National Agency for Medicines (present-day 
Finnish Medicines Agency, Fimea) approved Study II and Fimea was also notifi ed of Studies IV 
and V.
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5 RESULTS
Th e basic characteristics of the participants in Studies I – V are presented in Table 3. 
Table 3. Demographic data of participants.
 aOther diagnoses include miscellaneous states such as thrombocytosis, thrombocytopenia, infections, 
hypersedimentation or diagnosis unknown.
Study I Study II Study III Study IV Study V
Gender (male/female) 100/66 78/72 61/39 94/66 37/33
Age (years), mean (SD), range 53 (15),
17 - 87 
54 (14), 
18 - 82
56 (15),
19 - 89
59 (14),
19 - 89
59 (12),
17-80
Height (cm), mean (SD), range 172 (10),
149 - 197
172 (11),
153 - 204
174 (10),
145 - 190
172 (9.0),
153 - 193
172 (8.0),
150 - 186
Weight (kg), mean (SD), range 76.5 (16),
42 - 130
76.0 (17),
46 - 125
77 (14),
40 - 111
75 (14),
43 - 115
78 (15),
52 - 130
Site of aspiration, n
- Sternal manubrium
- Sternal body
- Iliac crest
36
27
100
62
11
77
21
28
51
31
27
102
8
8
54
Diagnoses, n
- Lymphoma
- Leukaemia
- Myeloma
- Myelodysplastic 
syndrome
- Other malignancy
- Anaemia
- Healthy donor
- Othera
32
59
9
5
5
9
9
41
19
80
5
8
7
4
5
22
16
44
10
1
3
2
3
21
26
47
17
7
14
4
4
41
11
19
7
3
2
6
0
22
Performed by, n
- Doctors in training
- Specialists
36
130
40
110
40
60
88
72
41
29
5.1  Factors associated with pain during the bone marrow aspiraƟ on and 
biopsy
Anxiety was a predictor of procedural pain in all trials. In Study I, high anxiety scores were 
associated with pain during local anaesthetic infi ltration, puncture and aspiration, whereas in 
Study V it was associated with aspiration pain only. In conclusion, anxiety can be regarded as one 
of the most important factors predicting procedural pain during BMAB. 
Being a fi rst-timer had an eff ect on pain scores in Studies I, II and V, but the eff ect was 
ambiguous: it was related to both increased and decreased pain scores. Age was found to aff ect 
pain ratings in some studies (Studies I, III, IV); higher age was associated with lower pain scores. 
Women suff ered more pain during local anaesthetic infi ltration than men in Study V, but during 
other BMAB phases the pain scores were similar. When all trials were combined, the experience 
of the performing haematologist (specialist vs. specializing physician) had no clear eff ect on pain 
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scores. Pain and anxiety during previous BMABs or other minor medical procedures predicted 
pain during the present BMAB as (Studies I and III).
Patients using pain or anxiolytic medication (regular or temporary) did not have lower 
pain scores during BMAB (Studies I, III, IV, V). Th ere were 16/ 11/ 20/ 13 patients on regular 
and 15/ 11/ 19/ 6 patients on temporary pain medication, and 14/ 10/ 17/ 4 patients on regular 
and 8/ 4/ 9 / 2 patients on temporary anxiolytic medication in Studies I/ III/ IV/ V, respectively. 
In some studies (Studies I, III), premedication with intramuscular alfentanil was allowed upon 
patient request, with no signifi cant pain-alleviating eff ect during bone marrow sampling, despite 
alleviating pain during local anaesthetic infi ltration (Study III). Premedication with diazepam 
had varying eff ects: in Study I, no eff ect was found, whereas in Study III aspiration pain was 
slightly lower. However, due to the small number of patients receiving premedication with 
diazepam, no conclusions can be drawn about its eff ectiveness. 
In Study I, patients described the quality of pain felt during BMAB with words belonging 
mostly to the sensory class (mainly words indicating punctate, incisive or constrictive pressure). 
However, aspiration pain was described also with aff ective words, indicating a diff erent quality of 
pain than in the other BMAB phases.
5.2  Anxiety during bone marrow aspiraƟ on and biopsy
5.2.1 Anxiety scores 
Th e median score of pre-procedural anxiety was relatively low in all trials: 38 (range 20 – 71, 
IQR 15) measured with STAI-S in Study I, 1 (range 0 – 4, IQR 4, where 0 = no anxiety, 4 = very 
anxious) in Study II, 3.0 (range 0 – 10, IQR 4) measured with NRS in Study III, 3.0 (range 0 – 10, 
IQR 4) measured with NRS in Study IV and 3.5 (range 0 – 10, IQR 5) measured with NRS in 
Study V. However, in every trial, some patients were extremely anxious.
5.2.2  Factors infl uencing anxiety
Factors related to higher levels of anxiety are presented in Table 4. Female gender was the only 
variable associated with high pre-procedural anxiety in all trials. In Study II, also younger age 
and being a BMAB fi rst-timer intensifi ed anxiety, but this association was not evident in the 
other studies. Pain, anxiety and nausea during previous BMABs were associated with higher 
anxiety scores, as were pain and anxiety during other previous minor medical procedures (Study 
I). 
Table 4. Factors related to intensifi ed pre-procedural anxiety. NS = non-signifi cant. 
Variable Statistical signifi cance
Study I Study II Study III Study IV Study V
Gender P = 0.022 P < 0.001 P < 0.001 P = 0.023 P = 0.02
Age NS P = 0.002 NS NS NS
First-timers NS P = 0.008 NS NS NS
Painful previous 
BMABs
P < 0.001 - P < 0.001 - NS
Anxiolytic 
medication
P = 0.019 - NS NS NS
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5.3  ArƟ caine infi ltraƟ on anaesthesia
Patients receiving articaine 20 mg/ml or 40 mg/ml, all with adrenaline 5 μ/ml, had similar pain 
scores as patients receiving lidocaine 20 mg/ml with adrenaline 5 μ/ml, and no statistically 
signifi cant diff erences were detected. Figure 5 presents the distribution of the pain scores. B iopsy 
pain seemed to be slightly lower in patients receiving articaine, but this diff erence did not reach 
statistical signifi cance. 
Results
Figure 5. Pain scores presented as boxplots (Study II).
5.4  Warming and buﬀ ering lidocaine soluƟ on
Pain during local anaesthetic infi ltration was signifi cantly less intense in patients receiving 
warmed and buff ered lidocaine compared with unmodifi ed solution (OR 0.29, 95% CI [0.13; 
0.62], P = 0.002, NRS median 2.0 vs. 4.0). However, no statistically signifi cant diff erences 
emerged in pain scores during other phases of BMAB in the adjusted analysis. In the unadjusted 
analysis, patients receiving warmed and buff ered lidocaine suff ered more pain during aspiration 
(OR 2.10, 95% CI [1.05; 4.22], P = 0.036, NRS median 5.0 vs. 3.5). Figure 6 shows the pain scores 
during BMAB as boxplots.  
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Figure 6. Pain scores presented as boxplots (Study III). 
5.5  Sublingual fentanyl
Sublingual fentanyl proved to be ineff ective in relieving pain during BMAB. Th e pain scores 
were similar in both groups (Figure 7), and no statistically signifi cant diff erences in pain scores 
emerged. However, patients receiving sublingual fentanyl suff ered signifi cantly more dizziness 
than patients receiving placebo (P < 0.0001, OR 7.24, 95% CI [2.69; 19.46]). Patients who vomited 
aft er the procedure (n = 4) had all received sublingual fentanyl. Nevertheless, fentanyl did not 
cause excessive sedation, as all patients remained within the awake levels of the sedation scale 
RSS. Furthermore, no signifi cant drops occurred in the peripheral oxygen saturation values. 
Results
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Figure 7. Distribution of pain scores presented as boxplots (Study IV).
5.6  Nitrous oxide
Patients who inhaled 50% N2O in oxygen had similar pain scores during BMAB as patients 
inhaling 50% oxygen. Figure 8 shows the distribution of pain scores. Four patients (3 from the 
placebo group) needed an additional local anaesthetic infi ltration. Nitrous oxide was relatively 
well tolerated; only one patient felt slightly nauseous aft er receiving nitrous oxide, 7 patients had 
transient dizziness (5 patients had received nitrous oxide, 2 patients placebo) and 3 patients (all 
from the placebo group) had headache. Nitrous oxide did not have adverse eff ects on cognitive 
function measured with the Letter Digit Coding Test. When patients were asked whether they 
would like to receive the same analgesia during the next BMAB, 30/35 patients (86%) in the 
N2O/O2 group and 29/35 patients (83%) in the placebo group answered yes.
Results 
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Figure 8. Pain scores presented as boxplots (Study V). 
5.7  Telephone interviews
During the telephone interview performed on the following day by the research assistant or 
another member of the study group some patients reported local reactions, such as haematoma 
or minor bleeding, redness or edema, at the puncture site. Th ere were no reports of serious 
complications caused by the procedure, although two patients (Studies IV and V) reported 
experiencing a sensory and motor block of the lower extremity, presumably due to abnormal 
distribution of the local anaesthetic to lumbar plexus nerves, and another patient (Study IV) 
developed an infection of the puncture area and needed treatment with intravenous antibiotics.  
Th e median pain score at this telephone interview on the day following the procedure was 
0 (range 0 – 7, IQR 1) when all trials were combined. Some participants (14.8%) had taken pain 
medication at home (mostly paracetamol or ibuprofen). 
Study II included a second telephone interview 2 weeks aft er the BMAB. At this point, most 
patients (92.6%) were pain-free and reported good general condition. 
Results
 
30
6  DISCUSSION
Th ese studies showed that although the majority of patients undergoing BMAB suff ered 
only minor or moderate procedural pain, some patients (4.7% – 13.9%) suff ered intense or 
excruciating pain (NRS 8 – 10). Premedication with sublingual fentanyl or inhaled nitrous oxide 
during the procedure were not helpful in reducing the pain, nor was intramuscular alfentanil 
or oral diazepam, given at the request of some participants. Patient’s own medication for pain 
or anxiety also did not ease pre-procedural anxiety or BMAB-related pain. Th e use of articaine 
for infi ltration analgesia instead of the regularly used lidocaine or warming and buff ering the 
lidocaine solution did not ease procedural pain, although warming and buff ering did reduce 
pain during local anaesthetic infi ltration. A clear fi nding was that pre-procedural anxiety is a 
major risk factor predicting procedural pain. 
Anxiety and pain during BMAB
Studies I – V showed a clear association between pre-procedural state anxiety and pain during 
BMAB. Th e association between anxiety and pain during BMAB has been noted in other studies 
as well (Lidén et al., 2009; Tanasale et al., 2013). In these studies, in addition to pre-procedural 
state anxiety, anxiety about needle insertion (Lidén et al., 2009) and outcome of the examination 
(Lidén et al., 2009; Tanasale et al., 2013) were associated with pain during BMAB. Anxiety is 
established to intensify pain during other medical procedures as well (Maggirias and Locker, 
2002; Ylinen et al., 2009) and following surgery (Ozalp et al., 2003). 
Patients with painful memories from previous BMABs or from other minor procedures were 
found to suff er more intense anxiety and pain during the present BMAB than other patients. 
Th is fi nding is in line with results from other studies with patients undergoing BMAB (Degen et 
al., 2010) or with dental patients (Maggirias and Locker, 2002). Furthermore, in another study 
conducted with dental patients, pre-procedural anxiety predicted post-procedural recall of 
pain intensity and its unpleasantness (Gedney et al., 2003). Th us, previous painful and adverse 
memories intensify pre-procedural anxiety and procedural pain and, through the intensifi ed 
anxiety level, may also aff ect post-procedural recollection of pain. Nevertheless, this may aid 
in identifying patients more prone to pain: adequate premedication and other pain-relieving 
methods could be aimed specifi cally at patients reporting high levels of anxiety and painful 
memories of previous BMABs. However, it is noteworthy that patients who had taken pain or 
anxiolytic medication at home did not suff er less pain during BMAB than the others. Moreover, 
in Study I, anxiolytic medication was related to an increased level of anxiety. Th us, regular need 
for pain and/or anxiolytic medication might itself be regarded as a risk factor for pain during 
BMAB. 
Female gender was associated with higher scores of anxiety relative to males in all trials. 
Th is association has already been noted in surgical patients during the preoperative phase 
(Karanci and Dirik, 2003; Yilmaz et al., 2012), in patients undergoing gastrointestinal endoscopy 
(Eberhardt et al., 2006) and in dental patients, especially younger females (Holtzman et al., 
1997). However, procedural pain scores during BMAB did not diff er between the genders, expect 
in Study V, where pain caused by local anaesthetic infi ltration was more intense in women than 
in men. 
Increasing age was associated with lower scores of anxiety (Study II) and procedural pain 
(Studies I, III, IV). In other studies examining pain during BMAB, a similar inverse correlation 
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between age and pain has been noted (Vanhelleputte et al., 2003; Lidén et al., 2009; Talamo et al., 
2010; Tanasale et al., 2013). Although there is evidence of decreased inhibitory pain modulation 
(Edwards et al., 2003) and altered pain thresholds (Lautenbacher et al., 2005) in older patients, 
acute, procedural pain appears to be better tolerated in the elderly population during several 
medical procedures (Li et al., 2001; Takahashi et al., 2005). Increasing age may have positive 
eff ects on life experiences and stress tolerance, which facilitate acceptance of painful stimuli.  
ArƟ caine infi ltraƟ on anaesthesia for BMAB
Study II failed to show any signifi cant diff erences in pain scores between patients receiving 
articaine and lidocaine infi ltration. However, the use of articaine has been found to lead to 
anaesthetic success more oft en than lidocaine in dentistry (Katyal, 2010). Nevertheless, since 
many trials are conducted with 4% articaine and 2% lidocaine, the higher amount of local 
anaesthetic molecules in the articaine solution may in part contribute to the better quality results 
with articaine (Becker and Reed, 2012). In Study II, the comparison with 2% lidocaine (20 mg/
ml) was made using two articaine concentrations, 2% (20 mg/ml) and 4% (40 mg/ml). Although 
the diff erences were non-signifi cant, the proportion of patients suff ering moderate or intense 
pain (NRS ≥ 4) was slightly lower in patients receiving articaine 20 mg/ml than lidocaine 20 
mg/ml during aspiration. Th e diff erence was even greater during puncture and biopsy, when 
articaine 40 mg/ml was compared with lidocaine 20 mg/ml. 
Th e two-minute latency period between infi ltration of the local anaesthetic and beginning 
of the procedure is relatively short. Since the pKa of both articaine and lidocaine is higher 
than the pH 7.4 of subcutaneous tissue in healthy subjects, the molecules are predominantly 
in their water-soluble, ionized form aft er the infi ltration, which delays the onset of anaesthesia 
(Becker and Reed, 2012). However, in the case of articaine, lipophilicity may increase when 
an intramolecular hydrogen bond forms (Skjevik et al., 2011). Although the bone-penetrating 
capacity of articaine has been shown to be superior to lidocaine (Vree and Gielen, 2005), the 
benefi cial eff ect may not be evident if the molecules have insuffi  cient time to diff use and infi ltrate 
the entire thickness of the bone tissue. At least in dentistry, the onset of satisfactory anaesthesia 
in a tooth may take several minutes for both articaine and lidocaine (Corbett et al., 2008). 
Warmed and buﬀ ered lidocaine for infi ltraƟ on
Th e skin and periosteum have nociceptors that react to, for instance, temperature, chemical 
composition changes of surrounding tissue medium and pressure. Excessive stimulation 
eventually leads to sensation of pain. (Koltzenburg, 2000) As the local anaesthetic solutions 
containing adrenaline are manufactured to be acidic in order to preserve the adrenaline, the 
infi ltration of the solution causes irritation of these nociceptors, which leads to sensation of pain. 
If the solution is taken directly from the refrigerator, the cold injectate further intensifi es pain. 
In Study III, pain during local anaesthetic infi ltration was signifi cantly less intense when the 
lidocaine solution was warmed to 32°C and buff ered to a pH of 7.3 (NRS median 2.0 vs. 4.0). 
Th e warmed and buff ered solution was prepared just prior to its use. Buff ered solutions may be 
stable for weeks if adequately preserved, but addition of adrenaline shortens the preservation 
time (Davies, 2003). 
A recent meta-analysis revealed that buff ering the local anaesthetic solution leads to less 
intense infi ltration pain (Hanna et al., 2009). Th is eff ect has been noted during BMAB as well 
(Ruegg et al., 2009). Th e study by Ruegg et al. showed that pain during all BMAB phases was 
Discussion
32
less intense when buff ered solution was used. However, Study III failed to show any clinically or 
statistically signifi cant diff erence in pain scores other than those during infi ltration.  
Warmed local anaesthetics have been shown to cause less pain than room-temperature 
solutions (Hogan et al., 2011) and the pain during infi ltration is of similar intensity as that of 
buff ered lidocaine (Brogan et al., 1995).  
In conclusion, the evidence for signifi cantly lowered pain intensity during infi ltration of 
buff ered and warmed solution is clear, and thus, warming and buff ering should be routinely 
carried out prior to local anaesthetic administration. Furthermore, buff ering and warming 
the solution is not diffi  cult or time-consuming. Studies I – V showed that pain during local 
anaesthetic infi ltration is intense (NRS 8 – 10) in surprisingly many patients (8.1%), indicating 
that more attention should be paid to techniques for reducing this pain.  
Overall eﬃ  cacy of local anaesthesia for BMAB
Besides the periosteum, the bone marrow is richly innervated by sensory nerves (Mach et 
al., 2002; Jimenez-Andrade et al., 2010), and the pain originating from these nerves may be 
impossible to eliminate by a subcutaneous infi ltration of a local anaesthetic, particularly if it is 
allowed to diff use for only a couple of minutes. Intraosseous infi ltration of the local anaesthetic 
solution is possible during specifi c dental procedures (Bigby et al., 2006). However, for BMAB, 
it is probably not conceivable, as local anaesthetics may cause cell damage (Werdehausen et al., 
2012) and distort cell morphology (Nicolson et al., 1976). Th is probably would hinder proper 
diagnostics of bone marrow tissue. Furthermore, due to the dense vasculature of the bone 
marrow, the local anaesthetic may be absorbed to the systemic circulation, increasing the risk of 
side-eff ects.  In conclusion, although local anaesthetic infi ltration is relatively eff ective in relieving 
pain originating from skin, subcutaneous tissue and the periosteum, the pain originating from 
the deeper bone tissue may require additional methods of pain relief, at least in patients having 
intense pre-procedural anxiety. 
PremedicaƟ on with sublingual fentanyl  
Study IV did not show any reductions in the pain scores of patients receiving sublingual fentanyl 
compared with placebo. Another signifi cant fi nding from this study was that sublingual fentanyl 
caused dizziness signifi cantly more oft en than placebo. Nausea and vomiting were also more 
common in patients receiving fentanyl.  Th is limits the use of the drug in outpatient settings, as 
the side-eff ects should be tolerable, allowing discharge home soon aft er the procedure. 
As the sublingual formulation of fentanyl is relatively new, no earlier studies have yet 
investigated its use for BMAB or other medical procedures. Oral transmucosal fentanyl, the older 
fentanyl “lollipop” formulation, has been noted to be eff ective in treating pain during BMAB in 
a paediatric population (Schechter et al., 1995), although nausea was common. Its feasibility as 
a premedication for medical procedures other than BMAB has been examined in, for instance, 
patients undergoing retinal photocoagulation (Hillier et al., 2009), gynaecological brachytherapy 
(Proud, 2007) and general surgery (Macaluso et al., 1996). Furthermore, it has proved to be 
benefi cial as a fi rst-line treatment of pain caused by battlefi eld injuries (Wedmore et al., 2012) 
and in treatment of migraine attacks (Landy, 2004). In general, oral transmucosal fentanyl has 
been shown to be eff ective in reducing acute pain of non-cancer origin, and in most cases, the 
side-eff ects have been tolerable. However, some of these studies have lacked a control group, 
randomization or blinding. 
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In conclusion, sublingual fentanyl in doses of 100 μg and 200 μg was not suffi  cient as a 
premedication for BMAB, as the pain-relieving eff ect did not reach statistical nor clinical 
signifi cance and side-eff ects were common. If the dose was increased to levels used for cancer 
breakthrough pain (300 – 800 μg) (Nalamachu et al., 2012), the respiratory and emetic side-
eff ects would probably be unacceptable in an outpatient population. Nevertheless, in selected 
patients, such as those having intense pre-procedural anxiety or painful memories from previous 
BMABs, it might be justifi ed to consider premedication with moderate doses of sublingual 
fentanyl. Sublingual administration would in any case be more pleasant than intramuscular or 
intravenous administration. Future studies should aim at identifying patients who would profi t 
from premedication with sublingual fentanyl. Its eff ectiveness in this patient population should 
also be determined. 
Nitrous oxide during BMAB
Study V showed that in an unselected outpatient population undergoing BMAB inhalation of 
the mixture of 50% nitrous oxide in oxygen (N2O/O2) was no more eff ective than inhalation of 
placebo (50% O2) in alleviating procedural pain. Th e evidence from previous studies performed 
with adult patients undergoing BMAB has been inconsistent, and moreover, some of the studies 
showing positive results have been either small, non-randomized or not blinded (Steedman et 
al., 2006; Gudgin et al., 2008). Th e only randomized, placebo-controlled study of a relatively 
small sample size (Johnson et al., 2008) showed that inhaled nitrous oxide is eff ective in relieving 
BMAB pain in men, but not in women. 
Although adequate analgesia was not achieved with nitrous oxide in Study V, the gas 
administration proved to be safe, with gas causing no more adverse eff ects than placebo. Nitrous 
oxide had no measurable eff ect on cognitive function assessed 30 minutes aft er BMAB, indicating 
that patients can be discharged soon aft er completion of the procedure provided that they feel 
well and have no related complications such as extensive bleeding. 
Nitrous oxide is a greenhouse gas (Ishizawa, 2011) that has been shown to cause occupational 
health risks for medical personnel (Sanders et al., 2008). Th us, if nitrous oxide is administered, 
measures should be taken to ensure that the gas is used properly (e.g. with the use of demand 
valves), that medical personnel is not exposed to harmful concentrations of the gas (gas 
scavenging systems or devices destroying the exhaled nitrous oxide, such as Excidio®) and that 
the patient and medical personnel are adequately guided on how to use the gas administration 
system. 
In conclusion, the overall evidence of the usefulness of inhaled nitrous oxide during BMAB 
is defi cient and more randomized controlled trials are needed before it can be recommended as 
a routine analgesic and sedative during BMAB in adult populations. In addition, not all patients 
need pain medication other than a local anaesthetic, so it is advisable to adequately select the 
patients most prone to pain for administration of inhaled nitrous oxide. 
Physicians, nurses and other medical professionals should remember that BMAB is a source 
of intense, even excruciating pain and anxiety for many patients. Th e suff ering of patients should 
not be underestimated. 
LimitaƟ ons of the study
Although the association between pain and anxiety was clear, there might have been confounding 
factors that were left  unadjusted. For example, the indication for the procedure varied among 
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participants; some were healthy bone marrow donors, whereas others had a suspected or 
diagnosed malignant disease. Th is probably had an eff ect on the intensity of pre-procedural 
anxiety and further on the procedural pain. Possible chronic anxiety or other psychiatric states 
might have aff ected the state of pre-procedural anxiety as well.
In Studies I and III – V, the level of experience of the performing physician was adjusted. 
Level of experience had an eff ect on pain only in Study IV: puncture pain was slightly lower during 
BMABs performed by doctors in training compared with specialists. However, contradictory 
results also exist (Vanhelleputte et al., 2003). Th e studies were not specifi cally powered to 
investigate the diff erence between doctors in training and specialists, which might explain our 
fi nding that the level of experience of the performing doctor did not have a signifi cant eff ect on 
pain during all phases of BMAB. 
Th e patients were asked to score the procedural pain during ongoing BMAB (Studies II 
– IV) or during the post-procedural interview (Studies I, V). Th e time of the interview itself 
might have aff ected the pain scores. In Study I, the pain scores were obtained aft er the procedure 
because they were derived from a special pain vocabulary, the learning of which demanded 
some time and consideration from the patient. In Study V, obtaining the scores during ongoing 
BMAB would have disturbed the continuous inhalation of the study gas. However, in the post-
procedural interview the relief felt aft er the completed procedure might have reduced the pain 
scores in Studies I and V. Furthermore, in some cases the patients might have had problems 
in diff erentiating between the BMAB phases aft er the completed procedure, which could have 
caused further bias in the pain scores.
Th e success of blinding was not controlled by asking the patients about the group to 
which they thought they were assigned. In Study III, the performing physician probably felt 
the diff erence between syringes containing warmed or room-temperature local anaesthetic. 
Furthermore, Study III was only patient-blinded. In Studies IV and V, patients might have been 
able to guess the group into which they were randomized due to possible adverse eff ects of the 
study drug. In Study V, the personnel in the procedure room were able to recognize the study 
group from the diff erence in the masks in the N2O/O2 and placebo groups.
Some factors limit the interpretation of the results of Study IV. As the time latency from 
receiving the study drug to the beginning of BMAB varied, it is possible that some patients did 
not fully achieve the pharmacological eff ects of fentanyl. Furthermore, some patients might have 
swallowed the drug. Th e pharmacokinetic profi le of sublingual administration is compromised if 
the drug is swallowed, possibly leading to suboptimal analgesia.
Study V was performed in an unselected group of patients undergoing BMAB. Th erefore, the 
research population was heterogeneous with regard to pain sensitivity and grade of anxiety, and 
many patients had both low pain scores and low anxiety scores regardless of the study group. Th us, 
the benefi cial eff ect of nitrous oxide compared with placebo may have been lost due to inclusion 
of patients not benefi ting from supplemental analgesia in the fi rst place. Th e gas administration 
demanded very close patient contact by the investigating staff , including instructions on how to 
hold the mask and how to breathe, and measurement of blood pressure. One cannot exclude that 
the exceptional nursing attention and attendance of an anaesthesiologist may have infl uenced 
the patient’s satisfaction with the procedure despite the pain. Th is assumption is supported by 
the fact that over 80% of the patients in both study groups would have desired the same gas 
treatment during their next BMAB.
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7  CONCLUSIONS
Based on these studies, the following conclusions can be drawn:
1. Th e intensity of pain during BMAB is associated with acute pre-procedural state anxiety; 
a high level of anxiety is related to a higher score of pain. Female gender is associated with 
higher anxiety scores. Patients with a history of painful or anxiety-provoking BMABs 
suff er more pain during the subsequent BMABs. Age seems to have an inverse correlation 
with pain. Pain during BMAB was mostly described with sensory words, although during 
aspiration aff ective words were also used. 
2. Articaine was as eff ective as lidocaine as a local anaesthetic for BMAB.  
3. Warming and buff ering the lidocaine solution that contained adrenaline diminished 
the intensity of pain during infi ltration signifi cantly compared with room-temperature, 
unmodifi ed lidocaine with adrenaline. However, pain during the subsequent BMAB phases 
did not diff er between patients receiving warmed and buff ered lidocaine and those receiving 
unmodifi ed lidocaine.
4. Sublingual fentanyl administered before BMAB was not eff ective in reducing pain, as the 
pain scores were similar in the fentanyl and placebo groups. Adverse eff ects (dizziness and 
nausea) were signifi cantly more common in patients receiving fentanyl. 
5. Patients receiving inhaled 50% nitrous oxide in oxygen did not have lower pain scores than 
patients inhaling placebo gas. Nevertheless, nitrous oxide was safe and did not cause serious 
side-eff ects or adverse eff ects on cognition. 
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8  FUTURE IMPLICATIONS
Pain and anxiety associated with BMAB continue to be signifi cant problems for many patients 
because nociceptive pain from the richly innervated bone marrow seems to be diffi  cult to 
eliminate with conscious sedation and analgesia. Patients who are likely to suff er intense pain 
during BMAB should be recognized in advance, and analgesics and sedatives should be aimed 
specifi cally at these patients. Risk factors for pain during BMAB are anxiety, young age and 
pain and anxiety during previous BMABs. Future studies should concentrate on these patients 
specifi cally. Th e clinical feasibility and eff ectiveness of analgesics and sedatives, such as inhaled 
nitrous oxide and benzodiazepines, should be evaluated in randomized, controlled studies 
performed with patients recognized to be at risk of suff ering intense pain during BMAB. Deep 
conscious sedation and analgesia with, for example, propofol and remifentanil might be useful 
for those patients most prone to pain. Buff ered local anaesthetics should always be used, as 
buff ering markedly reduces pain during infi ltration.
Attention directed to the mechanical performance of the procedure could be benefi cial as 
well, as evidence suggests that the powered bone marrow biopsy system causes less pain than 
conventional puncture methods. 
Future implications
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